Barclays
TSRX

Barclays’s TRIUS THERAPEUTICS INC COM STK (DE) TSRX Stock Holding History

Barclays’s Portfolio TSRX Stock Details TSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,551
Closed -$21K – 7893
2013
Q2 		$21K Buy
+2,551
New +$18.8K ﹤0.01% 6828

Other funds holding TSRX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.3B AUM 21.14% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Barclays's TSRX Position: Q3 2013 in Review

Barclays sold out of TRIUS THERAPEUTICS INC COM STK (DE) (TSRX) in Q3 2013, closing a stake of 2,551 shares — an estimated $21K sold.

Barclays first reported a position in TSRX in Q2 2013 and held it in 1 quarter. The position peaked at $21K in Q2 2013. 7 funds tracked by Wall St. Rank hold TSRX as of Q3 2013.

  • Barclays reported no remaining TRIUS THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Barclays sold 2,551 TRIUS THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $21K.
  • Barclays first reported a position in TRIUS THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Barclays's TRIUS THERAPEUTICS INC COM STK (DE) position peaked at $21K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held TRIUS THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on Barclays's 13F filing for Q3 2013, filed 14 Nov 2013.